Business Insider

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to ...
Healthline

Drugstore Nasal Spray May Cut COVID-19 Risk by 69%, Cold Risk by 71%

Share on Pinterest A new trial shows that a common nasal spray may help lower the risk of contracting COVID-19 and other respiratory illnesses. Professional Studio Images/Getty Images Researchers say ...
The Hamilton Spectator

Nasal naloxone spray: nowhere to be found

Pharmacies in Vancouver’s Downtown Eastside, both big and small, are out of nasal naloxone — the life-saving spray that reverses opioid overdose. London Drugs confirmed the shortage over the phone, ...
Fox News

COVID-19 infection risk cut 'significantly' with simple nasal spray, research finds

A new study has discovered another way to potentially prevent COVID-19. Researchers at Saarland University in Germany headed a clinical trial that found a nasal spray could reduce the risk of ...
Investing

ARS Pharmaceuticals receives Paragraph IV notice from Lupin for neffy nasal spray

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a pharmaceutical company with a market capitalization of $1.33 billion and strong financial health according to InvestingPro analysis, reported that on August ...
Mena FN

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results And Highlights Accelerating Growth For Neffy® (Epinephrine Nasal Spray)

(MENAFN- GlobeNewsWire - Nasdaq) $15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor ...
Everyday Health

The Best Saline Nasal Sprays for Easier Breathing and Better Sleep

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...
Morningstar

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA) ...
manilatimes

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients ...

The availability of neffy 1 mg extends protection to younger, school-aged children-who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as ...
Morningstar

FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.
Benzinga.com

3SPRY : FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray...

FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Get our list of 10 ...